In the clinical cohorts, TADA3 is down-regulated in NEPC vs AD (>2-fold), while KDM4B is up-regulated (>5 fold); however, only the deregulation of TADA3 is statistically significant (VPC P = 0.003 and WCM P = 0.017). This evidence concerns the gene KDM4B and Alzheimer disease.